Immunology News and Research

Latest Immunology News and Research

FDA approves Novartis Pharmaceuticals' Zortress for preventing rejection of kidney transplants

The US Food and Drug Administration (FDA) has approved Zortress® (everolimus) oral tablets for the prevention of rejection of kidney transplants in adult patients at low-to-moderate immunologic risk. Zortress is to be given in combination with reduced doses of the calcineurin inhibitor (CNI) cyclosporine, as well as basiliximab and corticosteroids.

22 Apr 2010

Seattle Genetics, Agensys present ASG-5ME ADC preclinical data at 101st AACR

Seattle Genetics, Inc. and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today reported preclinical data with ASG-5ME, an antibody-drug conjugate (ADC) that is being co-developed by both companies for the treatment of solid tumors. In models of human prostate and pancreatic cancer, ASG-5ME was found to have potent and long lasting antitumor activity. The findings were presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR) being held in Washington, D.C.

22 Apr 2010

No more needles for vaccines – a two minute Nanopatch may suffice, say researchers

Vaccines have been associated with painful injections for a very long time. In a new and important discovery researchers have developed special ‘nano patches’ that can deliver vaccines without needles in just two minutes using 100 times less dose than used conventionally.

22 Apr 2010

Abbott acquires Facet Biotech

Abbott has completed its acquisition of Facet Biotech Corporation, strengthening its pharmaceutical pipeline in immunology and oncology.

22 Apr 2010

Catabasis Pharmaceuticals to advance program targeting type 2 diabetes with $39.6 million Series A financing

Catabasis Pharmaceuticals, a biopharmaceutical company developing novel therapeutics for the treatment of inflammatory and metabolic diseases, today announced it has completed a $39.6 million Series A financing led by SV Life Sciences, Clarus Ventures, and MedImmune Ventures. Also participating in the round is Advanced Technology Ventures.

21 Apr 2010

Abbott's first-quarter worldwide pharmaceutical sales increases by 12.9%

Abbott today announced financial results for the first quarter ended March 31, 2010.

21 Apr 2010

A*STAR's BMRC and SIgN award grants for twelve research projects on infectious diseases and immunology

Twelve research projects on infectious diseases and immunology have been awarded grants by A*STAR's Biomedical Research Council (BMRC) and Singapore Immunology Network (SIgN) this year.

21 Apr 2010

Modest weight reduction reverses immune cell damage in obese people with diabetes

Australian scientists have shown for the first time that even modest weight loss reverses many of the damaging changes often seen in the immune cells of obese people, particularly those with Type 2 diabetes.

21 Apr 2010

ABRAXANE-bevacizumab combination therapy may exhibit potential in treatment of triple-negative breast cancers

Abraxis BioScience, Inc., a fully integrated biotechnology company, announced study results today that demonstrate a regimen of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) given in combination with bevacizumab (Avastin®) may have potential in the treatment of triple-negative breast cancers.

21 Apr 2010

Certain genetic mutations lead to Type 1 diabetes: The Scripps Research Institute

Scientists from The Scripps Research Institute have provided an answer to the 40-year-old mystery of how certain genetic mutations lead to Type 1 diabetes. This new molecular understanding could lead to novel therapies for Type 1 diabetes and other autoimmune diseases.

20 Apr 2010

S1P5 may serve as future strategy in biotherapy for esophageal cancer: Study

Esophageal cancer is one of the most common malignancies worldwide. Its mortality is very high due to relatively late diagnosis and inefficient treatment. The ability to reverse the outcome of esophageal cancer is limited due to a poor understanding of its biology. Progression of esophageal cancer may be associated with sphingosine 1-phosphate and its receptors S1P1-5, which play an important role in other cancers.

20 Apr 2010

Viral Genetics relocates research facilities to Georgetown

Biotech company Viral Genetics, Inc.,, is relocating its research facilities to the life science cluster in Georgetown, Texas. Lead scientist Dr. Karen Newell has joined the faculty of Texas A&M University's College of Medicine and has received a $750,000 grant to research bio-fuels from the Texas Emerging Technology Fund.

20 Apr 2010

Encorium Group reports 21.4% decrease in fourth-quarter net revenue

Encorium Group, Inc., a full service multinational clinical research organization conducting studies in over 30 countries for many of the world's leading pharmaceutical and biotechnology companies, today announced its financial results for the fourth quarter and year ended December 31, 2009.

20 Apr 2010

SPI-Bio to distribute and sell Aterovax's sPLA2 activity test in Europe

Aterovax SA, a company developing innovative products for atherosclerosis, today announced the signing of a 3 year, exclusive agreement with SPI-Bio, a specialist distributor of products and services in drug development, to distribute and sell Aterovax's sPLA2 activity test in Europe to academic and research laboratories for research use.

19 Apr 2010

Pivotal preclinical data of YM BioSciences' CYT387 JAK1/2 inhibitor pre-published in Blood

YM BioSciences Inc., announced the pre-publication of pivotal preclinical data for CYT387, the company's highly selective and potent JAK1/2 inhibitor, currently in a Phase I/II trial for myelofibrosis.

19 Apr 2010

Radiolabeled hedgehog can differentiate stem-like cancer cells, identify aggressive tumors

At the American Association for Cancer Research 101st Annual Meeting 2010, scientists and clinicians will present more than 6,300 abstracts dealing with innovative aspects of biology, technology and emerging therapies.

19 Apr 2010

Results of study comparing REMICADE to azathioprine for Crohn's disease published

Findings published today in The New England Journal of Medicine from a first-of-its-kind comparator trial evaluating the anti-tumor necrosis factor (TNF)-alpha biologic treatment REMICADE (infliximab) in the treatment of moderately to severely active Crohn's disease in patients who were naive to immunomodulator and biologic therapy, showed that a significantly greater proportion of patients receiving REMICADE achieved steroid-free remission and mucosal healing compared with patients receiving azathioprine.

16 Apr 2010

Laquinimod may have neuroprotective properties in addition to anti-inflammatory effects for RRMS

Teva Pharmaceutical Industries Ltd. and Active Biotech today announced results from several studies demonstrating that laquinimod, a novel, investigational once-daily oral immunomodulator for relapsing remitting multiple sclerosis (RRMS) may have neuroprotective properties in addition to its anti-inflammatory effects.

16 Apr 2010

Positive interim data from Idera Pharmaceuticals' Phase 1 trial of IMO-2125 TLR9 agonist presented at 45th EASL

Idera Pharmaceuticals, Inc. announced today that positive interim data from a Phase 1 clinical trial of IMO-2125, a Toll-like Receptor 9 (TLR9) agonist, in null responder patients with chronic hepatitis C virus (HCV) infection were presented at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL).

16 Apr 2010

Low levels of vitamin D associated with lower lung function in children with asthma

Low levels of vitamin D are associated with lower lung function and greater medication use in children with asthma, according to researchers at National Jewish Health. In a paper published online this week in the Journal of Allergy & Clinical Immunology, Daniel Searing, MD, and his colleagues also reported that vitamin D enhances the activity of corticosteroids, the most effective controller medication for asthma.

16 Apr 2010

Immunology News and Research

Latest Immunology News and Research

FDA approves Novartis Pharmaceuticals' Zortress for preventing rejection of kidney transplants

Seattle Genetics, Agensys present ASG-5ME ADC preclinical data at 101st AACR

No more needles for vaccines – a two minute Nanopatch may suffice, say researchers

Abbott acquires Facet Biotech

Catabasis Pharmaceuticals to advance program targeting type 2 diabetes with $39.6 million Series A financing

Abbott's first-quarter worldwide pharmaceutical sales increases by 12.9%

A*STAR's BMRC and SIgN award grants for twelve research projects on infectious diseases and immunology

Modest weight reduction reverses immune cell damage in obese people with diabetes

ABRAXANE-bevacizumab combination therapy may exhibit potential in treatment of triple-negative breast cancers

Certain genetic mutations lead to Type 1 diabetes: The Scripps Research Institute

S1P5 may serve as future strategy in biotherapy for esophageal cancer: Study

Viral Genetics relocates research facilities to Georgetown

Encorium Group reports 21.4% decrease in fourth-quarter net revenue

SPI-Bio to distribute and sell Aterovax's sPLA2 activity test in Europe

Pivotal preclinical data of YM BioSciences' CYT387 JAK1/2 inhibitor pre-published in Blood

Radiolabeled hedgehog can differentiate stem-like cancer cells, identify aggressive tumors

Results of study comparing REMICADE to azathioprine for Crohn's disease published

Laquinimod may have neuroprotective properties in addition to anti-inflammatory effects for RRMS

Positive interim data from Idera Pharmaceuticals' Phase 1 trial of IMO-2125 TLR9 agonist presented at 45th EASL

Low levels of vitamin D associated with lower lung function in children with asthma

Immunology eBook

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology